soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM soul trial oral semaglutide cardiovascular

Read more on MIMS Pharma To view or add a comment, sign in Overview of GLP-1 Analogue Drugs: Brands, Companies & Clinical Uses GLP-1 analogues have transformed the treatment landscape for Type 2 Diabetes and obesity management offering better glycemic control, cardiovascular benefits, and effective weight loss

Best Uses for IV Treatment IV glutathione therapy is especially valuable when fast or intensive antioxidant support is required

In many cases, uninsured patients pay significantly less than insurance copays for brand-name alternatives

Especially if you are already suffering from thyroid problems, always consult your health expert

Naltrexone (TRMP3 variant): A 2019 cell study using CFS/ME cells from 8 different patients showed that Naltrexone restored TRPM3 function.[ref] Keep in mind that this is just a cell study (not a randomized, double-blind, placebo-controlled trial), but it may be worth talking with your doctor about this study, especially if you carry a TRPM3 variant linked to CFS

doi:10.1016/j.jhep.2017.07.005